Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. near authorization of Johnson & Johnson COVID-19 vaccine

Published 02/26/2021, 06:24 AM
Updated 02/26/2021, 07:51 PM
© Reuters. FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration

© Reuters. FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration

By Manas Mishra and Michael Erman

(Reuters) - U.S. regulators on Friday said they would work quickly to authorize Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine for emergency use after a panel of outside advisers backed the one-shot immunization.

The Food and Drug Administration is expected to decide on emergency use by Saturday for what would be the third vaccine available in the United States, and the only one that requires a single shot.

The agency told J&J that "it will rapidly work toward finalization and issuance of an emergency use authorization," the regulator said in a statement after the vote by advisers.

"The agency has also notified our federal partners involved in vaccine allocation and distribution so they can execute their plans for timely vaccine distribution," it said.

The outside panel consisting of doctors, infectious disease experts and medical researchers voted unanimously that the benefits of the vaccine outweigh its risks in people age 18 and over.

“We believe our COVID-19 vaccine candidate has the potential to help change the trajectory of the pandemic and stand ready to make it available to protect the public as soon as possible,” Dr. Paul Stoffels, J&J's chief scientific officer said in a statement.

The company said it is prepared to supply its vaccine immediately if it receives emergency use authorization (EUA), as expected. J&J has said it will be able to ship three million to four million doses of its vaccine next week.

The company expects to have enough supply to vaccinate 20 million people by the end of March.

Senior White House adviser Andy Slavitt tweeted that the FDA would meet to finalize the EUA on Saturday. "A third safe and effective vaccine is very welcome news," he said.

More than 50 million vaccine shots have been administered nationwide, a milestone highlighted by President Joe Biden on Thursday.

But the emergence of highly contagious new virus variants has heightened the urgency to get hundreds of millions more people inoculated against the coronavirus. COVID-19 has claimed the lives of more than a half a million people in the United States.

Panel member Jay Portnoy, professor of pediatrics at the University of Missouri-Kansas City School of Medicine, said the race was on to stop the pandemic before new virus variants cause further disease.

"The fewer people who are infected with the virus, the less opportunity it has to emerge as a more virulent strain. So we're in a hurry to get this vaccine out," he said.

The head of the U.S. Centers for Disease Control and Prevention on Friday expressed concern that a recent decline in U.S. COVID-19 cases may be stalling.

In a 44,000-person trial, the J&J vaccine overall was 66% effective at preventing moderate-to-severe cases of COVID-19 compared with a placebo.

Two-dose vaccines made by Pfizer Inc (NYSE:PFE) with BioNTech SE (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) Inc were about 95% effective in their pivotal trials. Experts cautioned against drawing too much of a distinction between the vaccines because the trials had somewhat different goals, and importantly, the Pfizer/BioNtech and Moderna studies were conducted before the more transmissible virus variants had emerged in South Africa, Brazil and the UK.

J&J's trial was under way when the new variants were circulating and even prevalent in some countries where it was tested.

Still, its vaccine was 100% effective at preventing hospitalizations 28 days after vaccination and there were no COVID-19 deaths among those who received the shot.

During the meeting, a J&J vaccine executive said the company was developing a second-generation vaccine that would target the concerning South African variant and will be ready to start Phase I trials by this summer.

The J&J vaccine can be stored in normal refrigerator temperatures, making distribution easier than for the Pfizer/BioNTech and Moderna shots that use messenger RNA technology and are shipped frozen.

© Reuters. Vial of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate is seen in an undated photograph

J&J's vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.

Latest comments

From what i have read, ard 70%, or 230 million people, need to be inoculated in USA before reaching heard immunity. With the current speed they are administering the vaccines and with one more vaccine available, only requiring one shot, I am optimistic US will reach heed immunity before summer is over. Can start seeing the light at the end of the tunnel now. Just hope it doesnt take too long before they approve one of the vaccines to inoculate children.
good news
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.